In June we heard from the team running the COM-COV trial giving results of mixed vaccine schedules on the immune responses of people in the trial, when doses 1 and 2 were given four weeks apart.
The team are now publishing data from COM-COV2 which looks at immunogenicity, safety, and reactogenicity of mixed COVID-19 primary vaccination (doses 1 and 2) when the interval between doses 1 and 2 was 8-12 weeks (an average gap of nine weeks).
Trial participants (who had had either Pfizer or Oxford-AstraZeneca as their first dose) received either the same vaccine, or Moderna or Novavax, for their second dose. The results have been published in the Lancet.
Journalists dialled in to this press briefing to hear the scientist leading the trial explain the results and answer any questions.
Prof Matthew Snape, Associate Professor in Paediatrics and Vaccinology, University of Oxford, Chief Investigator on the trial
This Briefing was accompanied by an SMC Roundup of Comments.